FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a method for preparing a medicinal agent containing vardenafil hydrochloride trihydrate in the solid form wherein vardenafil hydrochloride trihydrate is treated with suitable pharmaceutical additives at temperature from approximately 20°C to approximately 45°C. The ambient relative humidity of the procedure makes 30% to 90%. The treated medicinal agent is film-coated at temperature within the range from 40°C to 55°C.
EFFECT: method according to the invention provide the additional stage of repeated hydration for the purpose of preparing the trihydrate form of vardenafil hydrochloride.
20 cl, 3 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICINES CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE | 2003 |
|
RU2349306C2 |
| METHOD OF OBTAINING MEDICAL FORM OF TRIMETAZIDINE OF PROLONGED ACTION | 2012 |
|
RU2530558C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING PYRIMIDIN -A-ONE DERIVATIVE, COVERED WITH INTESTINE-SOLUBLE POLYMER | 2004 |
|
RU2359660C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ROSUVASTATIN CALCIUM SALT (VERSIONS) | 2015 |
|
RU2606592C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PRODRUG OF HCV POLYMERASE INHIBITOR | 2010 |
|
RU2489153C2 |
| PROLONGED ACTION PHARMACEUTICAL COMPOSITION BASED ON 5-ETHOXY-2-[2-(MORPHOLINO)-ETHYLTHIO]BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE (APHOBAZOLUM) | 2017 |
|
RU2694837C2 |
| ORAL SOLID PREPARATION OF COMPOUND ANTITUBERCULOSIS DRUG AND PREPARATION METHOD THEREOF | 2012 |
|
RU2605388C2 |
| COMPOSITION FOR TREATING DISTURBED INNERVATION (VERSIONS) | 2013 |
|
RU2536269C1 |
| SOLID DOSAGE FORM OF AVATROMBOPAG AND METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2769863C1 |
